合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午，2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家，研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍， 2024年中国医学装备市场规模达到 1.35万亿 元，同比增长 6％ 左右 。据了解，目前我国已形成22个大类1100多个 品类的产品体系，是世界上产品类别和品种最齐全的国家之一，产品广泛服务于临床应用，覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中，哪些企业凭借创新亮相引起了行业关注？又有哪些前沿产品和技术成为焦点？思宇将全面回顾展会精彩亮点，供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品， 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ，以及多款前沿技术产品， 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...

Latest technology offers more applications and innovation across more specialtiesMAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics ...

Core Insights - Inari Medical, now part of Stryker, has launched the Artix Thrombectomy System, designed specifically for the peripheral arterial system, aiming to set a new standard for arterial thrombectomy [1][2][4] Product Overview - The Artix Thrombectomy System combines aspiration and mechanical thrombectomy, providing procedural control and versatility for treating arterial blood clots [1][2] - It is Inari's first product targeting the arterial space, building on the success of its venous thrombectomy devices [2][4] Clinical Significance - The system addresses a critical clinical need for effective treatment of chronic thrombi and aims to reduce the risk of clot migration [4] - Dr. Jonathan Bowman, who performed the first commercial case, highlighted its effectiveness in managing a wide range of clots while maintaining vessel access [3][4] Key Features - The Artix system includes a dual mechanical thrombectomy and aspiration toolkit, designed to remove acute to chronic clots in a single session [7] - It features an 8 Fr. low profile, trackable, kink-resistant sheath available in 65cm and 90cm lengths, enhancing treatment options for complex interventions [7] - The innovative over-the-wire mechanical element is designed to effectively collect and retrieve clots, while a covered nitinol mesh funnel minimizes the risk of arterial clot migration during procedures [7][9] Company Background - Stryker, a global leader in medical technologies, acquired Inari Medical on February 19, 2025, to enhance its portfolio in treating venous and arterial diseases [5][4] - Stryker impacts over 150 million patients annually through its innovative products and services across various medical fields [4]

Core Insights - Stryker has launched the Steri-Shield 8 personal protection system, enhancing its leadership in medical technologies and personal protective equipment [1][2] - The launch aligns with Stryker's strategy of continuous innovation and complements its existing product portfolio [1][2] Product Features and Benefits - Steri-Shield 8 features a customizable helmet with a secure fit and a ponytail path for long-haired users, enhancing comfort and usability [4] - The helmet offers a 22% wider field of vision and improved lighting compared to previous versions, along with a targeted cooling system for user comfort [4][5] - The system includes AAMI Level 4 protection, providing the highest fluid and microbial barrier for healthcare professionals [5] Market Performance - Stryker's shares declined by 1.3% following the launch, influenced by broader market weakness, while the company’s shares have increased by 6.6% year-to-date, outperforming the industry [3] - The S&P 500 Index has seen a decline of 0.9% during the same period [3] Financial Performance - In Q4 2024, Stryker reported revenues of $6.44 billion, a 10.7% year-over-year increase, with an adjusted EPS of $4.01, exceeding market expectations [9] - The company achieved organic sales growth of 10.2%, particularly strong in Instruments, Endoscopy, and Trauma & Extremities segments [9] Strategic Focus - Stryker's recent divestiture of its Spinal Implants business allows for a focus on high-growth areas such as interventional spine and enabling technologies [10] - The acquisition of Inari Medical signifies Stryker's commitment to expanding into high-potential medical markets [10] Complementary Innovations - The Steri-Shield 8 launch complements Stryker's existing MedSurg and Neurotechnology segments, particularly in Instruments and Endoscopy, which have shown strong performance [6] - Recent innovations like the Pangia plating system and LIFEPAK 35 defibrillator have also driven market interest, supporting Stryker's focus on safety and efficiency [8]

Core Insights - Stryker has launched the Steri-Shield 8 personal protection system, enhancing safety and wearability for healthcare professionals [1][2] - The system includes a customizable helmet, a sleeker battery, an efficient charging station, and three toga styles [2] Product Features - The helmet features three points of contact for an adjustable fit and includes a ponytail path for long-haired users [4] - Enhanced visibility is provided with a brighter helmet light and a 22% wider field of vision compared to the previous generation [4] - The fan design targets the front and back of users' necks to maintain comfort [4] - The togas offer AAMI level 4 protection, ensuring the highest fluid and microbial barrier for healthcare professionals [4] Company Overview - Stryker is a global leader in medical technologies, impacting over 150 million patients annually through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3]

Core Insights - Stryker has launched the Sync Badge, a hands-free, wearable communication device aimed at improving collaboration among healthcare team members in patient care settings [1][2][3] Product Features - The Sync Badge enables voice command functionality, allowing care team members to connect with each other across different units and roles, facilitating quick and reliable communication [2][3] - It includes a dedicated panic button for emergencies, enabling team members to quickly request help while providing security personnel with the staff member's name and location [8] - The device features a Do Not Disturb (DND) mode, allowing users to focus on critical tasks while still being able to receive urgent calls if necessary [8] - Integration capabilities with various connected devices and software platforms allow the Sync Badge to receive alarms and critical notifications directly, enhancing workflow efficiency [8][9] Market Context - The introduction of the Sync Badge comes at a time when nursing shortages are prevalent, and healthcare environments are increasingly demanding, highlighting the need for tools that simplify workflows and enhance communication [3][4] - Stryker positions itself as a leader in medical technologies, impacting over 150 million patients annually through innovative products and services [6]

Company Overview - Stryker Corporation is represented by incoming CFO Preston Wells and VP of Finance, IR Jason Beach during Citi's 2025 Unplugged Medtech and Life Sciences Access Day [1]. Leadership Transition - Preston Wells acknowledges the challenge of stepping into a significant role but expresses confidence in the company's direction and vision [3]. - The company has well-defined targets and a clear vision for the future, indicating a strong leadership continuity under the guidance of Kevin and the existing leadership team [3]. Financial Goals - The company aims to maintain its trajectory in terms of top-line growth, operational margin, and earnings per share (EPS) goals [3].

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 近日，史赛克公布了2024年全球业绩财报信息， 净销售额达到226亿美元 （合约1640.76亿人民币），净销售额有机增长10.2%。 史赛克董事长兼首席执行官Kevin Lobo表示： "我们再度达成了全年双位数的有机销售增长佳绩，同时继续扩大调整后的营业利润率，并有力推动了调整后的每股收益增长。我们成功推出了多款新品，并 通过并购举措，进一步强化了在高增长终端市场的领地。感谢团队的杰出贡献，他们为史赛克在2025年乃至更长远未来的持续辉煌奠定了牢固的基石。" #财报详情 2024年净销售额 226亿美元 ，净销售额有机增长 10.2% ； 营业收入利润率 为1 6.3% 。调整后 营业收入利润率增长110bps至 25.3% ； 调整后每股收益为 12.19美元 ，增长 15.0% 。 美国及国际市场均表现卓越，其中，美国市场继续保持两位数的强劲增长达 11% ，国际市场也实现固定汇率下 9.8% 的增长。 | | | | Full Year Net ...

合作伙伴征集：2025全球手术机器人大会 相关阅读： 360亿收购！医疗科技巨头2025强势开局！ # 收购分 析 Needham & Co.的分析师预计，该交易将为史赛克的有机增长带来约30个基点的增长，毛利率将增长约70个基点，但交易 预计 将稀释史 赛克2025年每股收益的约2.4%。 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年2月19日，史赛克Stryker（纽约证券交易所代码：SYK）宣布，已完成先前宣布的对Inari Medical的收购。该公司上个月 宣布达成协议， 以 每股80美元 的现金收购 Inari Medical ，交易总价值约为 49亿美元 （ 合约360亿人民币 ）。 Inari Medical 是一家专注于静脉血栓栓塞症（VTE）治疗的公司，其产品包括用于治疗深静脉血栓和肺栓塞等疾病的机械血栓切除设备 。 Stryker董事长兼首席执行官 Kevin Lobo 表示："收购Inari Medical是我们在扩展介入性血管内产品组合方面的一个重要里程碑。我 们欢迎才华横溢的Inari团队加入Stry ...

Core Viewpoint - Stryker Corporation (SYK) has demonstrated strong performance in the medical technology sector, with significant growth driven by innovative products and robust demand across various segments, despite facing competitive pressures and a high valuation relative to the industry. Financial Performance - SYK's shares closed at $385.18, 5.2% below its 52-week high of $406.19, with a 13% gain over the past six months, outperforming Medtronic (MDT) but underperforming Boston Scientific (BSX) [1][3] - The company reported a strong fourth-quarter 2024 performance, with organic sales growth of 10.2%, driven by demand in Orthopaedics, MedSurg, and Neurotechnology [3][4] - Stryker achieved a 200-basis-point improvement in adjusted operating margin, reflecting effective pricing strategies and manufacturing efficiencies [4] Market Expansion and Innovation - Stryker is focusing on high-growth medical technology segments, including robotic-assisted surgery and advanced trauma solutions, which are expected to elevate its market growth [5][6] - The acquisition of Inari Medical allows Stryker to enter the $15 billion peripheral vascular market, enhancing its growth potential [7] - Stryker's R&D pipeline is strong, with upcoming product launches like Mako Spine and Mako Shoulder expected to drive future sales [8][9] Demand Drivers - Increased demand for capital equipment is supported by healthy hospital CapEx budgets, with strong sales in medical, instruments, and endoscopy divisions [13][14] - The rise in elective surgeries and the expansion of ambulatory surgery centers are critical growth drivers, with record highs in knee and hip surgeries performed in these settings [19][16] - Demographic trends, including an aging population, are contributing to increased demand for orthopedic and neurovascular interventions [18] Analyst Sentiment and Estimates - Analysts are bullish on Stryker's prospects, with sales and earnings expected to grow in the near term [20] - Zacks Consensus Estimates project sales of $24.47 billion for the current year, with an estimated year-over-year growth of 8.31% [22] - Earnings estimates for the current year are projected at $13.49 per share, reflecting a year-over-year growth of 10.66% [24] Valuation and Strategic Moves - SYK is currently trading at a forward P/E of 28.17X, above the industry average of 22.67X, indicating a stretched valuation [25] - The acquisition of Inari Medical is expected to boost sales by $590 million in the 2025 stub period, while divesting the Spinal Implant business may improve focus and profitability [29][30]